We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
Read MoreHide Full Article
Shares of Mind Medicine (MindMed) Inc. (MNMD - Free Report) have skyrocketed 154% in the past three months against the industry’s decline of 4.2%.
The company is progressing well with the development of its lead pipeline candidate MM120 (lysergide D-tartrate) for the treatment of generalized anxiety disorder (GAD).
FDA granted a breakthrough therapy designation to MM120 for treating GAD last month.
Also, last month, MNMD announced that the phase IIb MMED008 study, which evaluated a single oral dose of MM120 (100 µg) in GAD. The study met its key secondary endpoint by demonstrating clinically and statistically significant durability of activity seen through week 12 of treatment.
The data showed that MM120 maintained a clinically and statistically significant Hamilton Anxiety rating scale (HAM-A) reduction as compared with placebo at 12 weeks of treatment.
These were the factors driving the stock’s rise in the said time frame.
Image Source: Zacks Investment Research
Previously, MM120 had demonstrated rapid, clinically meaningful and statistically significant improvement on HAM-A versus placebo at week four of treatment, thereby meeting the primary endpoint of the MMED008 study.
MindMed plans to initiate a phase III study on MM120 in GAD during the second half of 2024.
Notably, MM120 is also being studied in other serious brain health disorders.
If successfully developed and upon potential approval, MM120 should be able to serve an area of high unmet medical need and generate significant revenues for the company.
MindMed is evaluating another candidate, MM-402, in an early-stage study for treating autism spectrum disorder in adult healthy volunteers.
2023 was a highly productive year for MindMed. Several additional milestones are expected in 2024 which could be important catalysts for the stock.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Year to date, shares of ADMA have rallied 41.4%.
ADMA’s earnings beat estimates in three of the trailing four quarters and met the same once, the average surprise being 85.00%.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 9.2%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, shares of ANIP have jumped 22.7%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
Shares of Mind Medicine (MindMed) Inc. (MNMD - Free Report) have skyrocketed 154% in the past three months against the industry’s decline of 4.2%.
The company is progressing well with the development of its lead pipeline candidate MM120 (lysergide D-tartrate) for the treatment of generalized anxiety disorder (GAD).
FDA granted a breakthrough therapy designation to MM120 for treating GAD last month.
Also, last month, MNMD announced that the phase IIb MMED008 study, which evaluated a single oral dose of MM120 (100 µg) in GAD. The study met its key secondary endpoint by demonstrating clinically and statistically significant durability of activity seen through week 12 of treatment.
The data showed that MM120 maintained a clinically and statistically significant Hamilton Anxiety rating scale (HAM-A) reduction as compared with placebo at 12 weeks of treatment.
These were the factors driving the stock’s rise in the said time frame.
Image Source: Zacks Investment Research
Previously, MM120 had demonstrated rapid, clinically meaningful and statistically significant improvement on HAM-A versus placebo at week four of treatment, thereby meeting the primary endpoint of the MMED008 study.
MindMed plans to initiate a phase III study on MM120 in GAD during the second half of 2024.
Notably, MM120 is also being studied in other serious brain health disorders.
If successfully developed and upon potential approval, MM120 should be able to serve an area of high unmet medical need and generate significant revenues for the company.
MindMed is evaluating another candidate, MM-402, in an early-stage study for treating autism spectrum disorder in adult healthy volunteers.
2023 was a highly productive year for MindMed. Several additional milestones are expected in 2024 which could be important catalysts for the stock.
Mind Medicine (MindMed) Inc. Price
Mind Medicine (MindMed) Inc. price | Mind Medicine (MindMed) Inc. Quote
Zacks Rank & Stocks to Consider
MindMed currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are ADMA Biologics, Inc. (ADMA - Free Report) , Ligand Pharmaceuticals Incorporated (LGND - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Year to date, shares of ADMA have rallied 41.4%.
ADMA’s earnings beat estimates in three of the trailing four quarters and met the same once, the average surprise being 85.00%.
In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have gained 9.2%.
Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, shares of ANIP have jumped 22.7%.
Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.